<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations can be detected in a variable number of patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, but are rare events in <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is good evidence supporting the involvement of <z:mp ids='MP_0011356'>RAS</z:mp> signalling pathway in <z:mp ids='MP_0005481'>CML</z:mp> and this could be due to alterations in <z:mp ids='MP_0011356'>RAS</z:mp> activity regulatory proteins </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> (NF1) gene down-regulates the <z:mp ids='MP_0011356'>RAS</z:mp> signal transduction pathway through the inhibitory function of its GAP-related domain (GRD) on <z:mp ids='MP_0011356'>RAS</z:mp> protein </plain></SENT>
<SENT sid="3" pm="."><plain>The loss or alteration of neurofibromin (the NF1 protein) may produce a disfunction similar to point mutations in the <z:mp ids='MP_0011356'>RAS</z:mp> gene resulting in the permanent stimulation of the <z:mp ids='MP_0011356'>RAS</z:mp> signal transduction pathway </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations involving the GRD region of the NF1 gene (GRD-NF1) have been described in a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> such as colon <z:mp ids='MP_0002038'>carcinoma</z:mp> and <z:hpo ids='HP_0009592'>astrocytoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Germline mutations and deletions in the NF1 gene, as seen in <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1, are also associated with certain myeloid disorders </plain></SENT>
<SENT sid="6" pm="."><plain>In the present work, we sought to identify mutations in the codons 12/13 and 61 of <z:mp ids='MP_0011356'>RAS</z:mp> gene and in the Lys-1423 codon of GRD-NF1, which are well known hot spots in these genes, in a group of 36 adults and ten children with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase and <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Using the PCR-SSCP and the allele-specific restriction assay (ASRA) techniques, we were not able to observe any <z:mp ids='MP_0011356'>RAS</z:mp> or NF1 detectable mutation </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that <z:mp ids='MP_0011356'>RAS</z:mp> and GRD-NF1 mutations are not involved either in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase or in the progression to <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> in <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in adults and children </plain></SENT>
</text></document>